Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

Friday’s trading has closed, but PFE is being traded in the after-hours session. After-Hours quote »
29.03
Delayed Data
As of 4:02pm ET
 +0.03 / +0.10%
Today’s Change
28.47
Today|||52-Week Range
36.46
-10.07%
Year-to-Date
Dow 30 Stock Roundup: Microsoft, Exxon Beat on Earnings, Chevron Incurs Loss
2:01pm / Zacks.com
3 Stocks Pulling The Drugs Industry Downward
Feb 01 / TheStreet.com
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
9:54am / Zacks.com
Investor calls for big pharma to slim down grow louder
Feb 01 / FT.com
5 Stunning Numbers From Pfizer's Q4 Report That You May Have Missed
Feb 03 / MotleyFool.com
Put Pfizer On Your Ratio Put Spread List
Feb 01 / TheStreet.com
PFIZER INC (PFE) Earnings Report: Q4 2015 Conference Call Transcript
Feb 02 / TheStreet.com
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Feb 01 / Zacks.com
Why Axovant Sciences Shares Are Crashing
Feb 02 / MotleyFool.com
Rally Hobbled As Ugly China Reality Replaces Japan NIRP Euphoria; Oil Rebound Fizzles
Feb 01 / Investing Channel
ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16
Feb 02 / Zacks.com
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q4?
Jan 29 / Zacks.com
Pfizer says US politicians will not scupper Allergan deal
Feb 02 / FT.com
3 Numbers That Will Matter When Pfizer Reports Its Fourth-Quarter Results
Jan 29 / MotleyFool.com
Why Opko Health's Shares Fell 20% in January
Feb 02 / MotleyFool.com
4 Reasons Why Johnson & Johnson Exploded Higher Following Its Q4 Earnings Release
Jan 28 / MotleyFool.com
Pfizer's Move on Alzheimer's Drug Is Bad News for Axovant
Feb 02 / TheStreet.com
Novartis (NVS) Lags Q4 Earnings & Revenues, Alcon Down
Jan 28 / Zacks.com
Energy and bank stocks lead the market down
Feb 02 / FT.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance
Jan 28 / Zacks.com
Q4 Earnings Illustrate Earnings Recession
Feb 02 / Zacks.com
Is Another Big Transformation on the Way for GlaxoSmithKline?
Jan 28 / MotleyFool.com
Pfizer Beats on Q4 Earnings, Revenues, Outlook Disappoints
Feb 02 / Zacks.com
J&J investors urge activists to press for shake-up
Jan 27 / FT.com
Earnings and Oil Drive Markets Lower While Alphabet Leapfrogs Apple
Feb 02 / TheStreet.com
Allergan's Botox Gains FDA Nod for Lower Limb Spasticity
Jan 26 / Zacks.com
Axovant Sinks on Pfizer Alzheimer's Drug Blowup
Feb 02 / TheStreet.com
England backs biosimilar challenger to Merck blockbuster
Jan 26 / FT.com
Pfizer (PFE) Stock Retreats in Pre-Market Trading on 2016 Guidance
Feb 02 / TheStreet.com
If You're in Your 60s, Consider Buying These Stocks
Jan 26 / MotleyFool.com
Pfizer (PFE) Tops on Q4 Earnings and Revenues
Feb 02 / Zacks.com
Forget Pfizer Inc.: Here Are 2 Better Dividend Stocks
Jan 26 / MotleyFool.com
Pfizer (PFE) Is Today's Pre-Market Laggard Stock
Feb 02 / TheStreet.com
Novartis (NVS) to Report Q4 Earnings: Will It Disappoint?
Jan 25 / Zacks.com
Feb. 2 Premarket Briefing: 10 Things You Should Know
Feb 02 / TheStreet.com
Johnson Controls strikes $20bn Tyco acquisition
Jan 24 / FT.com
Stocks: 6 things to know before the open
Feb 02 / CNNMoney.com
Pascal Soriot confident of AstraZeneca's independent course
Jan 21 / FT.com
What to Watch Tuesday: Yahoo! to Reveal Cost-Cutting Plan
Feb 01 / TheStreet.com
Drugmakers call for collective action on superbugs
Jan 20 / FT.com
Can GlaxoSmithKline (GSK) Q4 Earnings Surprise Estimates?
Feb 01 / Zacks.com
UCL raises B#50m to spin new companies out of research
Jan 18 / FT.com
Jim Cramer: Stop Thinking So Short Term About Biotech Stocks
Feb 01 / TheStreet.com
The stateless company plans a risky game
Jan 06 / FT.com
Jim Cramer on Pfizer (PFE): 'One of the Most Consistent Companies'
Feb 01 / TheStreet.com